Clarus Wins Ax Of Rival's Testosterone Patent Claims

By Jeannie O'Sullivan (June 1, 2021, 8:22 PM EDT) -- Clarus Therapeutics Inc. has convinced a federal judge to invalidate claims in four Lipocine Inc. patents that Clarus was accused of infringing with its testosterone replacement treatment Jatenzo, according to an opinion unsealed Tuesday.

Federal Circuit Judge William C. Bryson, sitting by designation in Delaware federal court, sided with Clarus' argument that the 24 asserted claims in the patents, which Lipocine contends were infringed by Jatenzo, were plagued by an inadequate written description. In his May 25 opinion, Judge Bryson agreed that the asserted claims were overly broad and that the lengthy specification provided "only limited and narrowly circumscribed support for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!